Switch theme
Sign up to access all valuation multiples
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
2011
229
LTM Revenue $84.1M
LTM EBITDA -$68.6M
$268M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Personalis has a last 12-month revenue (LTM) of $84.1M and a last 12-month EBITDA of -$68.6M.
In the most recent fiscal year, Personalis achieved revenue of $84.6M and an EBITDA of -$70.3M.
Personalis expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Personalis valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $84.1M | XXX | $84.6M | XXX | XXX | XXX |
| Gross Profit | $23.8M | XXX | $26.8M | XXX | XXX | XXX |
| Gross Margin | 28% | XXX | 32% | XXX | XXX | XXX |
| EBITDA | -$68.6M | XXX | -$70.3M | XXX | XXX | XXX |
| EBITDA Margin | -82% | XXX | -83% | XXX | XXX | XXX |
| EBIT | -$77.0M | XXX | -$68.3M | XXX | XXX | XXX |
| EBIT Margin | -92% | XXX | -81% | XXX | XXX | XXX |
| Net Profit | -$82.1M | XXX | -$81.3M | XXX | XXX | XXX |
| Net Margin | -98% | XXX | -96% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Personalis's stock price is $5.
Personalis has current market cap of $409M, and EV of $268M.
See Personalis trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $268M | $409M | XXX | XXX | XXX | XXX | $-1.19 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Personalis has market cap of $409M and EV of $268M.
Personalis's trades at 3.2x EV/Revenue multiple, and -3.8x EV/EBITDA.
Equity research analysts estimate Personalis's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Personalis has a P/E ratio of -5.0x.
See valuation multiples for Personalis and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $409M | XXX | $409M | XXX | XXX | XXX |
| EV (current) | $268M | XXX | $268M | XXX | XXX | XXX |
| EV/Revenue | 3.2x | XXX | 3.2x | XXX | XXX | XXX |
| EV/EBITDA | -3.9x | XXX | -3.8x | XXX | XXX | XXX |
| EV/EBIT | -3.5x | XXX | -3.9x | XXX | XXX | XXX |
| EV/Gross Profit | 11.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | -5.0x | XXX | -5.0x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -5.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialPersonalis's last 12 month revenue growth is 10%
Personalis's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.4M for the same period.
Personalis's rule of 40 is -122% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Personalis's rule of X is -57% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Personalis and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 10% | XXX | 11% | XXX | XXX | XXX |
| EBITDA Margin | -82% | XXX | -83% | XXX | XXX | XXX |
| EBITDA Growth | 16% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -122% | XXX | -73% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -57% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 58% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 112% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| EZZ Life Science | XXX | XXX | XXX | XXX | XXX | XXX |
| Epigenomics | XXX | XXX | XXX | XXX | XXX | XXX |
| ToolGen | XXX | XXX | XXX | XXX | XXX | XXX |
| 4basebio | XXX | XXX | XXX | XXX | XXX | XXX |
| Genus | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Personalis acquired XXX companies to date.
Last acquisition by Personalis was XXXXXXXX, XXXXX XXXXX XXXXXX . Personalis acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Personalis founded? | Personalis was founded in 2011. |
| Where is Personalis headquartered? | Personalis is headquartered in United States of America. |
| How many employees does Personalis have? | As of today, Personalis has 229 employees. |
| Who is the CEO of Personalis? | Personalis's CEO is Mr. Christopher Hall. |
| Is Personalis publicy listed? | Yes, Personalis is a public company listed on NAS. |
| What is the stock symbol of Personalis? | Personalis trades under PSNL ticker. |
| When did Personalis go public? | Personalis went public in 2019. |
| Who are competitors of Personalis? | Similar companies to Personalis include e.g. EZZ Life Science, Epigenomics, ToolGen, 4basebio. |
| What is the current market cap of Personalis? | Personalis's current market cap is $409M |
| What is the current revenue of Personalis? | Personalis's last 12 months revenue is $84.1M. |
| What is the current revenue growth of Personalis? | Personalis revenue growth (NTM/LTM) is 10%. |
| What is the current EV/Revenue multiple of Personalis? | Current revenue multiple of Personalis is 3.2x. |
| Is Personalis profitable? | Yes, Personalis is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Personalis? | Personalis's last 12 months EBITDA is -$68.6M. |
| What is Personalis's EBITDA margin? | Personalis's last 12 months EBITDA margin is -82%. |
| What is the current EV/EBITDA multiple of Personalis? | Current EBITDA multiple of Personalis is -3.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
